Anti-phospho-Sufu

Anti-phospho-Sufu polyclonal antibody recognises wild type sufu which is phosphorylated at serine 352. The antibody specificity for the phosphorylated version has been confirmed; it does not react against a non-phosphorylated version of Sufu which has serine 352 substituted by alanine.

Contributors

Inventor Institute
Vincenzo D'Angiolella University of Oxford
SKU: 153540
Product description: Anti-phospho-Sufu polyclonal antibody recognises wild type sufu which is phosphorylated at serine 352. The antibody specificity for the phosphorylated version has been confirmed; it does not react against a non-phosphorylated version of Sufu which has serine 352 substituted by alanine. Sufu is a negative regulator in the hedgehog signaling pathway which directs cell proliferation and patterning during embryogenesis. Sufu down-regulates GLI1- and GLI2-mediated transactivation of target genes and is part of a corepressor complex that acts on DNA-bound GLI1. Required for normal embryonic development. Sufu is ubiquitous in adult tissues. Heterozygous loss of Sufu, in conjunction with the loss of p53, leads to the development of medulloblastoma and rhabdomyosarcoma. Somatic Sufu mutations have been identified in multiple other malignancies, including prostate cancer.
Alternate name: Suppressor of fused homolog, SUFUH
Conjugation: Unconjugated
Molecular weight: ~65 kDa
Immunogen: Sufu peptide: Hu #347~360: CLESDS-pS-pT-AIIPHEL
Cat. #: 153540
Tool sub type: Primary antibody
Unit size: 100 ug
Research Fields: Cancer;Developmental biology;Genetics
Application: IF ; WB
Target: Sufu (UniProt ID: Q9UMX1)
Reactivity: Human ; Mouse
Host: Rabbit
Class: Polyclonal
Target background: Anti-phospho-Sufu polyclonal antibody recognises wild type sufu which is phosphorylated at serine 352. The antibody specificity for the phosphorylated version has been confirmed; it does not react against a non-phosphorylated version of Sufu which has serine 352 substituted by alanine. Sufu is a negative regulator in the hedgehog signaling pathway which directs cell proliferation and patterning during embryogenesis. Sufu down-regulates GLI1- and GLI2-mediated transactivation of target genes and is part of a corepressor complex that acts on DNA-bound GLI1. Required for normal embryonic development. Sufu is ubiquitous in adult tissues. Heterozygous loss of Sufu, in conjunction with the loss of p53, leads to the development of medulloblastoma and rhabdomyosarcoma. Somatic Sufu mutations have been identified in multiple other malignancies, including prostate cancer.
Format: Liquid
Concentration: 2 mg/ml
Storage conditions: -15° C to -25° C
Shipping conditions: Dry ice
References:

Raducu et al. 2016. EMBO J. 35(13):1400-16. PMID: 27234298.

SCF (Fbxl17) ubiquitylation of Sufu regulates Hedgehog signaling and medulloblastoma development.

Images

View Gallery
Detection of Sufu; phosphorylated S352 Sufu and HA after immunoprecipitation of HA tagged Sufu Wild Type and Sufu S352A from HEK293T cells. The top panel (pSufu (S352)) was probed with anti-phospho-Sufu polyclonal antibody showing the anti-phospho-Sufu polyclonal antibody is specific and recognises only the phosphorylated form of Sufu but not a mutant where S352 is mutated to alanine. In the middle panel (Sufu); an anti-Sufu polyclonal antibody was used to probe and shows the anti-Sufu polyclonal antibody binds to either form of Sufu independent of the phosphorylation status. The bottom panel shows the same immunoprecipitation preparations probed with an anti-haemagglutinin (HA) antibody; this detects both proteins via their HA tag.

Related Tools for Antibodies

Cat. # Tool Name
151015 Anti-CyclinA [E70.1] Key Info View Tool
151033 Anti-HSVUL42 [13C9] Key Info View Tool
151036 Anti-ICAM1 [15.2] Key Info View Tool
151038 Anti-Cytochrome P450 4A2, 4A3 [Clo4] Key Info View Tool
151018 Anti-Mos [R38.1] Key Info View Tool

Tool enquiry

Please ensure you use your organisation email address rather than personal where possible, as this helps us locate your organisation in our system faster.

Please note we may take up to three days to respond to your enquiry.

CancerTools.org uses the contact information provided to respond to you about our research tools and service. For more information please review our privacy policy.